SecBot SecBot

CNSY

CERENOME, INC.
Nasdaq· CIK 0001095981
$1.57 −0.07 (−4.27%)
Oct 26 4:00 PM ET · prev $1.64
Market cap
$13.3M
Nano cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$28.00
+1683% · range $12.00–43.00
Next earnings
Oct 28
in 1 day · EPS est. −$1.03
1 year
−89.5%
from $15.00 · Oct 27
30 days
−22.3%
from $2.02
52-week range
$1.56–18.00
−91% from high · low Oct 5
Avg volume 20D
166.8K
Oct 1 spike 1.17M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
Filing reports
4
analyzed by SecBot
SecBot read MIXED 6 reports · 90 days
Balance 2 bearish · 1 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 4/6 ·Next Earnings date, Oct 28, 2026
Strongest MIXED Cerenome reported Q2 2026 EPS of -$1.31, a 43.2% miss vs consensus of -$0.92, with revenue of $1.3M in line…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.860 → −$1.030 over 90 days. 0 up, 2 down in 30 days.

  • TrendDOWNTREND

    30% below its 50-day average.

Who's buying

13F
Top holderSharesValue
VANGUARD CAPITAL MANAGEMENT LLC304,745$1.3M
BlackRock, Inc.95,983$419.4K
GEODE CAPITAL MANAGEMENT, LLC76,155$332.9K
VANGUARD FIDUCIARY TRUST CO36,868$161.1K
STATE STREET CORP30,853$134.8K
CITADEL ADVISORS LLC25,597$111.9K
NORTHERN TRUST CORP15,516$67.8K
HRT FINANCIAL LP11,612$50.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy2Buy7Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +1683%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 1, 2026Lake Street
MAINTAIN
MAINTAINBuy
Sep 11, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
Jun 8, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Oct 28, 2026
Earnings date
CNSY Q3 2026 Earnings Scheduled — 2026-10-28
Recent
Oct 27, 2026
Company news
🔒 Fresh data, subscribers only
Oct 6, 2026
Press release
Cerenome Launches CNSide® CSF Molecular Profile Tests
Cerenome launches two CNSide CSF molecular profiling tests, expanding DNA and RNA testing across CNS cancers, available October 12.
Sep 30, 2026
Earnings
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Cerenome reports $1.55 million in preliminary Q3 CNSide gross billings, advances payer coverage and plans an expanded test menu in Q4.
Sep 25, 2026
Company news
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
Cerenome will host a CNSide business update conference call on September 30, 2026 at 8:30am ET.
Sep 22, 2026
Contract
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
Cerenome secures in-network agreement with BCBS Michigan, expanding CNSide’s contracted coverage to approximately 158 million covered lives.

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 1, 2026
Guse Kyle
Director
EXERCISE921 sh
Oct 1, 2026
van Es-Johansson An
Director
EXERCISE921 sh
Oct 1, 2026
Clowes Howard
Director
EXERCISE921 sh
Oct 1, 2026
Hawkins Richard J
Director
EXERCISE921 sh
Oct 1, 2026
Sims Andrew John Hugh MacIntyre
Chief Financial Officer
EXERCISE1,533 sh
Oct 1, 2026
Sims Andrew John Hugh MacIntyre
Chief Financial Officer
EXERCISE1,165 sh
Oct 1, 2026
Sims Andrew John Hugh MacIntyre
Chief Financial Officer
EXERCISE287 sh
Oct 1, 2026
ANDREWS RONALD ASBURY
Director
EXERCISE921 sh

Earnings setup

Estimates
Oct 28
reports in 1 day
−$1.03
EPS estimate, this quarter
−20%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.03-$1.11–-$0.98-15.4%$750.0K
Next Q-$0.97-$1.00–-$0.91-24.8%$1.6M
Current FY-$4.75-$5.11–-$4.40+4.9%$3.7M
Next FY-$2.48-$3.17–-$1.98-3.8%$19.1M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 Routine
🔒 Fresh data, subscribers only
Oct 2, 2026 SEC
Cerenome filed an 8-K on October 2, 2026, to furnish an updated corporate investor presentation (Exhibit 99.1) dated…
8-K — Impact 3/10
Oct 1, 2026 Insider
Guse Kyle acquired via exercise 921 shares
Director
Oct 1, 2026 Insider
van Es-Johansson An acquired via exercise 921 shares
Director
Oct 1, 2026 Insider
Clowes Howard acquired via exercise 921 shares
Director
Sep 30, 2026 SEC
Cerenome reported Q2 2026 EPS of -$1.31, a 43.2% miss vs consensus of -$0.92, with revenue of $1.3M in line with…
PRESS-RELEASE — Impact 6/10
Sep 22, 2026 Press
Cerenome subsidiary CNSide Diagnostics signed an in-network provider agreement with Blue Cross Blue Shield of…
Impact 5/10
Sep 16, 2026 Press
Cerenome subsidiary CNSide Diagnostics appointed Samantha Fowlkes as VP Head of Commercial Sales to lead commercial…
Impact 3/10

SecBot reports

4 filings · 2 press releases · 0 bullish · 2 bearish · 1 mixed · 1 neutral
All CNSY filing & press-release reports (6)